In addition, it has been shown that INSM1, by regulating the activity of C-MYC and p-ERK pathways, can promote breast cancer development [37], and a large clinical trial recommends INSM1 in cases of IBC with neuroendocrine differentiation [38]. Here, INSM1 is linked to inflammatory breast carcinoma.